La Jolla Pharmaceutical Company Announces Negative Results Of Interim Efficacy Analysis For Riquent Phase 3 ASPEN Trial
Main Category: LupusAlso Included In: Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry
Article Date: 16 Feb 2009 - 4:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  |
3 (2 votes) |
| Healthcare Prof: |  |
La Jolla Pharmaceutical Company (Nasdaq:LJPC) announced today that the Independent Data Monitoring Board for the Riquent® Phase 3 ASPEN study has informed the Company that they have completed the first interim efficacy analysis and determined that continuing the study is futile. The Company has decided to stop the study, unblind the data and evaluate the results. The Company expects to provide additional guidance on its strategic options going forward in the near future.
La Jolla Pharmaceutical Company
Visit our lupus section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/139152.php>
APA
http://www.medicalnewstoday.com/releases/139152.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
